Home › Obesity › North Carolina
Obesity clinical trials in North Carolina
62 studies for Obesity are looking for participants at sites in North Carolina.
Cities in North Carolina
- Durham20 studies
- Charlotte17 studies
- Havelock17 studies
- Wilmington15 studies
- Greensboro12 studies
- Cary8 studies
- Winston-Salem7 studies
- Statesville7 studies
- Raleigh6 studies
- Greenville5 studies
- New Bern4 studies
- Fayetteville4 studies
- Concord3 studies
- Shelby3 studies
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- PharmQuest Life Sciences LLC, Greensboro
- Piedmont Healthcare/Research, Statesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07668414A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Medication Management, LLC, Greensboro
- Accellacare - Wilmington, Wilmington
- Jeffrey Coleman, OD, Wilmington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07595549AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Medication Mgmnt, LLC_Grnsboro, Greensboro
- Accellacare of Raleigh, Raleigh
- Accellacare-Salisbury PMG Res, Salisbury
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07720271Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- TMA Headlands, Wilmington
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT07837973Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Medication Management /ID# 281965, Greensboro
- Monroe Biomedical Research /ID# 282009, Monroe
- Centricity Research - Morehead city /ID# 283264, Morehead City
- and 2 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07752979A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Statesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07776509AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
- UNC Eastowne Medical Office, Chapel Hill
- PharmQuest Life Sciences LLC, Greensboro
- Accellacare and KDCILM, LLC, Wilmington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07339423A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- UNC Children's Hospital, Chapel Hill
- Duke Children's Primary Care, Durham
- Lucas Research, Inc, Morehead City
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Sep 24, 2026 · NCT06672549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Coastal Research Institute - Fayetteville, Fayetteville
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Coastal Research Institute - Fayetteville, Fayetteville
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937086FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
- University of North Carolina at Chapel Hill, Chapel Hill
Recruiting
Ages 18 to 75 · All sexes · Updated Sep 23, 2026 · NCT06724406A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Monroe Biomedical Research, Monroe
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Novant Health Heart and Vascular Institute, Charlotte
- Velocity Clinical Research - Durham, Durham
- Moses H Cone Memorial Hospital, Greensboro
- and 7 more
RecruitingPhase 3
Ages 45 to 99 · All sexes · Updated Sep 22, 2026 · NCT07037433A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Monroe
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07784270A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- PharmQuest Life Sciences, LLC, Greensboro
- West Clinical Research, Morehead City
- Trial Management Associates - Wilmington - Floral Parkway, Wilmington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- University of North Carolina Medical Center, Chapel Hill
- Medication Management, Greensboro
- Carteret Medical Group, Morehead City
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07392190A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- and 1 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 22, 2026 · NCT07589608A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
- Carolina Research Center, Shelby
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07153471A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Charlotte
- AURORA-2 Clinical Site, Durham
- AURORA-2 Clinical Site, Greenville
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Charlotte
- AURORA-1 Clinical Site, Greenville
- AURORA-1 Clinical Site, Morehead City
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07743463Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Asheville Cardiology Associates, Asheville
- Duke University Health System, Durham
- Ima Clinical Research - Lenoir, Lenoir
- and 2 more
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Sep 16, 2026 · NCT07037459A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Lucas Research, Inc., Morehead City
- Shelby Clinical Research, Shelby
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 14, 2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Centricity Research Morehead City Multispeciality, Morehead City
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07351058Tirzepatide in Obesity-Driven Endometrial Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingEarly phase 1
Ages 18 and older · Women · Updated Sep 11, 2026 · NCT07065552A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Charlotte
- ACCOMPLISH-2 Research Site, Durham
- ACCOMPLISH-2 Research Site, Fayetteville
- and 2 more
RecruitingPhase 3Healthy volunteers welcome
Ages 18 to 79 · All sexes · Updated Sep 11, 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medication Management, Greensboro
- Monroe Biomedical Research, Monroe
- Lucas Research, Inc, Morehead City
- and 1 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 8, 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Revival Research Institute, LLC, Cary
- Onsite Clinical Solutions - Huntersville, Huntersville
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06857942A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- PharmQuest, Greensboro
- KDCILM, LLC & Accellacare US, Inc., Wilmington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07745504Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Accellacare of Hickory, Hickory
- Carolina Research Center Inc, Shelby
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07684235Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Greensboro
- Kailera Clinical Site, Monroe
- Kailera Clinical Site, Morehead City
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- West Clinical Research, Morehead City
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07684144Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Morehead City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07284875Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Morehead City
- Kailera Clinical Site, Morrisville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Centricity Research Morehead City Specialty, Morehead City
- Accellacare of Raleigh, Raleigh
- Accellacare Research of Wilmington, Wilmington
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Aug 27, 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Statesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07784725Using Tailored mHealth Strategies to Promote Weight Management Among Adolescent and Young Adult Cancer Survivors
- University of North Carolina at Chapel Hill, Chapel Hill
Recruiting
Ages 18 to 39 · All sexes · Updated Aug 24, 2026 · NCT06848491Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Levine Children's Hospital, Charlotte
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Peak Clinical Trials, Apex
- Hawthorne Health NC, Concord
- Duke University, Durham
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07567001AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Piedmont Healthcare/Research, Statesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07509307Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
- Monroe Biomedical Research, Monroe
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Aug 14, 2026 · NCT07226765From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.